PATENT CLAIM ANALYSIS

Application Number: 15759305
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Claim (Index 3):
The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to  claim 1 , wherein the antisense oligomer is (e) or (f) shown below:\n (e) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (e-1) to (e-6) shown below:\n (e-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions \u22124 to 25 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (e-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 112 to 131 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (e-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 128 to 142 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (e-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 169 to 206 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (e-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 209 to 228 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; and \n (e-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 331 to 365 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; or \n (f) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (f-1) to (f-7) shown below:\n (f-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 1 to 18 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (f-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 116 to 131 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (f-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 130 to 140 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (f-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 160 to 206 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (f-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 211 to 225 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (f-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 271 to 282 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; and \n (f-7) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 341 to 365 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 90.0
- Lexical Diversity: 1.38889
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15759267', '15314535', '14368307', '15122435', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8130765903431685
- 35 USC 102 Novelty (BERT): 0.5654408084329512
- Combined Prediction Score: 0.7883130121521468
- Mean Citation Score: 427.308318
- Max Citation Score: 475.8151
- Similarity Product: 363.8994804538905

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test